Menu Search
Equities

Abera Bioscience AB

8WK:FRA

Abera Bioscience AB

Actions
  • Price (EUR)0.358
  • Today's Change0.016 / 4.68%
  • Shares traded-1.00
  • 1 Year change-8.91%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abera Bioscience AB is a Sweden-based company, which is active in biotechnology. Abera Bioscience is platform and vaccine development company active in the medical, molecular and microbiological field. The Company’s purpose is to develop vaccine candidates based on its vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines. The technology is mainly used in the development of new vaccines where the focus is on the main areas of pneumococci and immunooncology. The business is located around the Nordic market.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-16.72m
  • Incorporated2012
  • Employees--
  • Location
    Abera Bioscience ABDragarbrunnsgatan 45, Box 1747UPPSALA 751 47SwedenSWE
  • Websitehttps://aberabio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.